Yabin Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yabin Ji has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Xiaowei Yang
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 shared publicationsXuezhen Xiao
Zhuhai Fudan Innovation Institute, Zhuhai, China
2 shared publicationsYao Xue
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany
2 shared publicationsBerthold Hocher
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany
1 shared publication- Bing Wen
Qilu Hospital of Shandong University
1 shared publication - Cheng Fang
National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by Springer Nature in Research Square
Sex Differences in Cluster Headache: Insights from the Chinese Cluster Headache Register Individual Study (CHRIS)
Background Sex differences in the clinical characteristics of cluster headache (CH) remain controversial in both Eastern and Western studies, and such differences have not been thoroughly investigated among Chinese patients. Methods This large-scale, multicenter cohort study included 1,206 patients from 31 provinces across China diagnosed with CH between May 2021 and December 2024, and was conducted within the framework of the Chinese Cluster Headache Register Individual Study. Demographic and clinical data were systematically collected from each participant using an electronic structured questionnaire, and compared all variables between sexes. Results In total, 1,206 patients were enrolled, with a female-to-male ratio of 1:3.94. Demographic analysis showed that women had an earlier mean age of onset, higher educational attainment, and fewer unhealthy lifestyle factors compared with men. Women were also more likely to have comorbid migraine (28.28% vs. 15.90%, P < 0.001) and psychological conditions such as anxiety and depression, and to use oral rizatriptan for acute treatment (27.78% vs. 15.80%, P < 0.001). With respect to cranial autonomic symptoms (CASs), women experienced eyelid edema (18.85% vs. 12.47%, P = 0.010) and ptosis (56.97% vs. 49.90%, P = 0.048) more frequently, and reported migraine-associated symptoms more often. Conversely, men more commonly presented with conjunctival hyperemia (56.03% vs. 38.52%, P < 0.001), rhinorrhea (47.92% vs. 38.93%, P = 0.012), and facial sweating (38.15% vs. 30.74%, P = 0.032). Women had significantly higher frequencies of attacks during the early morning hours (2:00–8:00), whereas men experienced significantly more attacks during midday (10:00–14:00) and evening (16:00–20:00). Conclusion This study provides the first comprehensive analysis of multidimensional sex differences in Chinese patients with CH, encompassing social characteristics, clinical phenotypes, psychological burden, and circadian attack distribution. These findings offer valuable evidence for developing precision medicine approaches and sex-specific clinical management strategies for CH.
- 10 December 2025
- Published by Springer Nature in Research Square
Open AccessSex Differences in Cluster Headache: Insights from the Chinese Cluster Headache Register Individual Study (CHRIS)
Background Sex differences in the clinical characteristics of cluster headache (CH) remain controversial in both Eastern and Western studies, and such differences have not been thoroughly investigated among Chinese patients. Methods This large-scale, multicenter cohort study included 1,206 patients from 31 provinces across China diagnosed with CH between May 2021 and December 2024, and was conducted within the framework of the Chinese Cluster Headache Register Individual Study. Demographic and clinical data were systematically collected from each participant using an electronic structured questionnaire, and compared all variables between sexes. Results In total, 1,206 patients were enrolled, with a female-to-male ratio of 1:3.94. Demographic analysis showed that women had an earlier mean age of onset, higher educational attainment, and fewer unhealthy lifestyle factors compared with men. Women were also more likely to have comorbid migraine (28.28% vs. 15.90%, P < 0.001) and psychological conditions such as anxiety and depression, and to use oral rizatriptan for acute treatment (27.78% vs. 15.80%, P < 0.001). With respect to cranial autonomic symptoms (CASs), women experienced eyelid edema (18.85% vs. 12.47%, P = 0.010) and ptosis (56.97% vs. 49.90%, P = 0.048) more frequently, and reported migraine-associated symptoms more often. Conversely, men more commonly presented with conjunctival hyperemia (56.03% vs. 38.52%, P < 0.001), rhinorrhea (47.92% vs. 38.93%, P = 0.012), and facial sweating (38.15% vs. 30.74%, P = 0.032). Women had significantly higher frequencies of attacks during the early morning hours (2:00–8:00), whereas men experienced significantly more attacks during midday (10:00–14:00) and evening (16:00–20:00). Conclusion This study provides the first comprehensive analysis of multidimensional sex differences in Chinese patients with CH, encompassing social characteristics, clinical phenotypes, psychological burden, and circadian attack distribution. These findings offer valuable evidence for developing precision medicine approaches and sex-specific clinical management strategies for CH.
- Open Access
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 6, 1686043
Therapeutic observation of transcutaneous auricular vagus nerve stimulation for chronic migraine in pediatric patients: a case report
Background: Although interest in migraine has increased in recent years, important gaps remain in understanding and optimizing its management. These gaps are particularly pronounced in pediatric migraine, which continues to be understudied. Case report: This case report demonstrates the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in an 8-year-old male patient with refractory chronic migraine with aura [two to three weekly episodes; visual analog scale (VAS): 5–9; duration of each episode was 24 h]. After discontinuing all prophylactic and abortive medications (except ibuprofen suspensions such as Motrin®), the patient underwent a 28-week taVNS protocol that involved the following phases: a 4-week acute intervention, a 4-week intermission period, a 12-week preventive intervention, and an 8-week follow-up. During the acute intervention phase, the patient’s headache duration decreased by 84.4%, and frequency was reduced to fewer than two episodes/week, with complete aura resolution. The preventive intervention yielded further improvement to fewer than 1 episode/week by week 8 (with a 37.5% reduction in medication use). At final follow-up, the patient maintained a medication-free status with only three mild episodes (VAS: 1–3; duration <30 min) in the last 4 weeks. No adverse events were observed. Conclusion: taVNS was effective and safe in the management of chronic migraine in the reported pediatric patient. These findings suggest the need for further evaluation of this non-pharmacological intervention in pediatric migraine.
- 10 November 2025
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 6, 1686043
Open AccessTherapeutic observation of transcutaneous auricular vagus nerve stimulation for chronic migraine in pediatric patients: a case report
Background: Although interest in migraine has increased in recent years, important gaps remain in understanding and optimizing its management. These gaps are particularly pronounced in pediatric migraine, which continues to be understudied. Case report: This case report demonstrates the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in an 8-year-old male patient with refractory chronic migraine with aura [two to three weekly episodes; visual analog scale (VAS): 5–9; duration of each episode was 24 h]. After discontinuing all prophylactic and abortive medications (except ibuprofen suspensions such as Motrin®), the patient underwent a 28-week taVNS protocol that involved the following phases: a 4-week acute intervention, a 4-week intermission period, a 12-week preventive intervention, and an 8-week follow-up. During the acute intervention phase, the patient’s headache duration decreased by 84.4%, and frequency was reduced to fewer than two episodes/week, with complete aura resolution. The preventive intervention yielded further improvement to fewer than 1 episode/week by week 8 (with a 37.5% reduction in medication use). At final follow-up, the patient maintained a medication-free status with only three mild episodes (VAS: 1–3; duration <30 min) in the last 4 weeks. No adverse events were observed. Conclusion: taVNS was effective and safe in the management of chronic migraine in the reported pediatric patient. These findings suggest the need for further evaluation of this non-pharmacological intervention in pediatric migraine.
- Open Access
Single-centre, randomised and double-blind clinical trial on the efficacy of transcutaneous auricular vagus nerve stimulation in preventing and treating primary headache in children and adolescents: a study protocol
Introduction Primary headaches pose a significant burden on children and adolescents, highlighting the need for effective non-pharmacological interventions. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive modality that has demonstrated efficacy in adult populations with primary headaches and has shown safety in adolescents with mental health disorders. However, its effectiveness in managing acute headache episodes and preventing recurrences in paediatric populations remains underexplored. This study aims to evaluate the immediate analgesic effects of taVNS during acute headache episodes and its preventive efficacy over a 4-week period. Additionally, we will investigate potential biomarkers associated with primary headaches and elucidate the underlying mechanisms of taVNS through electromyography (EMG) and electrocardiography (ECG) assessments. Methods and analysis This study will employ a double-blind, randomised clinical trial design involving 288 children and adolescent participants diagnosed with primary headaches. The study will consist of two substudies: the acute period (AP) study and the preventive period (PP) study. Participants will be randomly allocated to receive either taVNS or sham stimulation. The primary outcome for the AP study will be the reduction of pain intensity 2 hours after treatment, as measured by the visual analogue scale, while the PP study will assess the change in the headache attack days over the treatment period. Secondary outcomes will include EMG and ECG parameters. Ethics and dissemination The study will adhere to the principles outlined in the Declaration of Helsinki and has received ethical approval from the Medical Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2024–057), on 2 January 2024. Informed consent will be obtained from all participants or their guardians. The findings will be disseminated through peer-reviewed journals and presented at relevant scientific conferences. Trial registration number NCT06277063.
Open AccessSingle-centre, randomised and double-blind clinical trial on the efficacy of transcutaneous auricular vagus nerve stimulation in preventing and treating primary headache in children and adolescents: a study protocol
Introduction Primary headaches pose a significant burden on children and adolescents, highlighting the need for effective non-pharmacological interventions. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive modality that has demonstrated efficacy in adult populations with primary headaches and has shown safety in adolescents with mental health disorders. However, its effectiveness in managing acute headache episodes and preventing recurrences in paediatric populations remains underexplored. This study aims to evaluate the immediate analgesic effects of taVNS during acute headache episodes and its preventive efficacy over a 4-week period. Additionally, we will investigate potential biomarkers associated with primary headaches and elucidate the underlying mechanisms of taVNS through electromyography (EMG) and electrocardiography (ECG) assessments. Methods and analysis This study will employ a double-blind, randomised clinical trial design involving 288 children and adolescent participants diagnosed with primary headaches. The study will consist of two substudies: the acute period (AP) study and the preventive period (PP) study. Participants will be randomly allocated to receive either taVNS or sham stimulation. The primary outcome for the AP study will be the reduction of pain intensity 2 hours after treatment, as measured by the visual analogue scale, while the PP study will assess the change in the headache attack days over the treatment period. Secondary outcomes will include EMG and ECG parameters. Ethics and dissemination The study will adhere to the principles outlined in the Declaration of Helsinki and has received ethical approval from the Medical Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2024–057), on 2 January 2024. Informed consent will be obtained from all participants or their guardians. The findings will be disseminated through peer-reviewed journals and presented at relevant scientific conferences. Trial registration number NCT06277063.
- Open Access
- 28 March 2022
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 28 (6) , 862-872
Lithium attenuates blood–brain barrier damage and brain edema following intracerebral hemorrhage via an endothelial Wnt/β‐catenin signaling‐dependent mechanism in mice
Background: Vasogenic cerebral edema resulting from blood–brain barrier (BBB) damage aggravates the devastating consequences of intracerebral hemorrhage (ICH). Although augmentation of endothelial Wnt/β‐catenin signaling substantially alleviates BBB breakdown in animals, no agents based on this mechanism are clinically available. Lithium is a medication used to treat bipolar mood disorders and can upregulate Wnt/β‐catenin signaling.Methods: We evaluated the protective effect of lithium on the BBB in a mouse model of collagenase IV‐induced ICH. Furthermore, we assessed the effect and dependency of lithium on Wnt/β‐catenin signaling in mice with endothelial deletion of the Wnt7 coactivator Gpr124.Results: Lithium treatment (3 mmol/kg) significantly decreased the hematoma volume (11.15 ± 3.89 mm3 vs. 19.97 ± 3.20 mm3 in vehicle controls, p = 0.0016) and improved the neurological outcomes of mice following ICH. Importantly, lithium significantly increased the BBB integrity, as evidenced by reductions in the levels of brain edema (p = 0.0312), Evans blue leakage (p = 0.0261), and blood IgG extravasation (p = 0.0009) into brain tissue around the hematoma. Mechanistically, lithium upregulated the activity of endothelial Wnt/β‐catenin signaling in mice and increased the levels of tight junction proteins (occludin, claudin‐5 and ZO‐1). Furthermore, the protective effect of lithium on cerebral damage and BBB integrity was abolished in endothelial Gpr124 knockout mice, suggesting that its protective effect on BBB function was mainly dependent on Gpr124‐mediated endothelial Wnt/β‐catenin signaling.Conclusion: Our findings indicate that lithium may serve as a therapeutic candidate for treating BBB breakdown and brain edema following ICH.
- 28 March 2022
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 28 (6) , 862-872
Open AccessLithium attenuates blood–brain barrier damage and brain edema following intracerebral hemorrhage via an endothelial Wnt/β‐catenin signaling‐dependent mechanism in mice
Background: Vasogenic cerebral edema resulting from blood–brain barrier (BBB) damage aggravates the devastating consequences of intracerebral hemorrhage (ICH). Although augmentation of endothelial Wnt/β‐catenin signaling substantially alleviates BBB breakdown in animals, no agents based on this mechanism are clinically available. Lithium is a medication used to treat bipolar mood disorders and can upregulate Wnt/β‐catenin signaling.Methods: We evaluated the protective effect of lithium on the BBB in a mouse model of collagenase IV‐induced ICH. Furthermore, we assessed the effect and dependency of lithium on Wnt/β‐catenin signaling in mice with endothelial deletion of the Wnt7 coactivator Gpr124.Results: Lithium treatment (3 mmol/kg) significantly decreased the hematoma volume (11.15 ± 3.89 mm3 vs. 19.97 ± 3.20 mm3 in vehicle controls, p = 0.0016) and improved the neurological outcomes of mice following ICH. Importantly, lithium significantly increased the BBB integrity, as evidenced by reductions in the levels of brain edema (p = 0.0312), Evans blue leakage (p = 0.0261), and blood IgG extravasation (p = 0.0009) into brain tissue around the hematoma. Mechanistically, lithium upregulated the activity of endothelial Wnt/β‐catenin signaling in mice and increased the levels of tight junction proteins (occludin, claudin‐5 and ZO‐1). Furthermore, the protective effect of lithium on cerebral damage and BBB integrity was abolished in endothelial Gpr124 knockout mice, suggesting that its protective effect on BBB function was mainly dependent on Gpr124‐mediated endothelial Wnt/β‐catenin signaling.Conclusion: Our findings indicate that lithium may serve as a therapeutic candidate for treating BBB breakdown and brain edema following ICH.